A Phase II Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Women with Breast Cancer and Established Bone Metastases (MBD) - Women with Breast Cancer and Established Metastatic Bone Disease
A Two Year Study to Assess the Efficacy, Safety, and Tolerability of MK-0364 in Obese Patients Followed by a 1-Year Extension - A Two Year Study of MK-0364 in Obese Patients Followed by a 1-Year Extension
100 Clinical Results associated with MSD (Norge) AS
0 Patents (Medical) associated with MSD (Norge) AS
100 Deals associated with MSD (Norge) AS
100 Translational Medicine associated with MSD (Norge) AS